Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024 - Episode 4

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

,

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

EP. 1: Dissecting the Current Treatment Landscape in MDS
EP. 2: The Importance of Treating Anemia in MDS
EP. 3: Optimal Goals for Anemia and Transfusion Independence in MDS
Now Viewing
EP. 4: Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS
EP. 5: Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS
EP. 6: Other Potential Roles for Luspatercept in MDS And Beyond
EP. 7: Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS
EP. 8: The Potential of Oral HMAs in MDS

Related Content:

Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024The University of Texas MD Anderson Cancer CenterYale Cancer CenterMyeloproliferative NeoplasmsOncLive News Network®
Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
The Potential of Oral HMAs in MDS